Cardinal Health Stock Drops 7% Amid Acquisition and Q4 Earnings
PorAinvest
martes, 12 de agosto de 2025, 5:14 pm ET1 min de lectura
AENT--
Financial Highlights:
- Revenue: Q4 revenue was $60.2 billion, a 2% decrease from the previous year. Excluding the impact of a previously communicated customer contract expiration, revenue increased by 21% [1].
- Operating Earnings: GAAP operating earnings were $428 million, a 7% increase year-over-year (YoY). Non-GAAP operating earnings rose 19% to $719 million [1].
- EPS: GAAP diluted EPS was $1.00, while non-GAAP diluted EPS increased 13% to $2.08 [1].
- Acquisition: Cardinal Health announced the acquisition of Solaris Health, which will join the Specialty Alliance's Urology Alliance [1].
Stock Performance:
Cardinal Health's stock fell 7% after the announcement, with investors reacting to the acquisition's cost and the flat Q4 revenue. The company's shares traded at $120.50, down from $130.00 before the announcement.
Outlook:
Cardinal Health raised its 2026 non-GAAP EPS guidance to $9.30 to $9.50, a 13% to 15% increase from the previous guidance. The company expects revenue growth of 11% to 13% for the Pharmaceutical and Specialty Solutions segment, 2% to 4% for the Global Medical Products and Distribution segment, and 26% to 28% for the Other segment [1].
References:
[1] https://newsroom.cardinalhealth.com/2025-08-12-Cardinal-Health-Reports-Fourth-Quarter-and-Fiscal-Year-2025-Results-and-Raises-Fiscal-Year-2026-Guidance
CAH--
SLSR--
Cardinal Health stock fell 7% after announcing a $1.9 billion acquisition of Solaris Health, a urology MSO, and reporting flat Q4 revenue at $60.2 billion. Non-GAAP net income rose 11% to $501 million, or $2.08 per share. The company raised its 2026 guidance, forecasting adjusted EPS of $9.30 to $9.50.
Cardinal Health (NYSE: CAH) reported its fourth quarter (Q4) and full year (FY) 2025 results, with stock falling 7% after the announcement of a $1.9 billion acquisition of Solaris Health, a leading urology medical services organization (MSO). The company's Q4 revenue was relatively flat at $60.2 billion, while non-GAAP net income rose 11% to $501 million, or $2.08 per share. Cardinal Health also raised its 2026 earnings per share (EPS) guidance to $9.30 to $9.50 [1].Financial Highlights:
- Revenue: Q4 revenue was $60.2 billion, a 2% decrease from the previous year. Excluding the impact of a previously communicated customer contract expiration, revenue increased by 21% [1].
- Operating Earnings: GAAP operating earnings were $428 million, a 7% increase year-over-year (YoY). Non-GAAP operating earnings rose 19% to $719 million [1].
- EPS: GAAP diluted EPS was $1.00, while non-GAAP diluted EPS increased 13% to $2.08 [1].
- Acquisition: Cardinal Health announced the acquisition of Solaris Health, which will join the Specialty Alliance's Urology Alliance [1].
Stock Performance:
Cardinal Health's stock fell 7% after the announcement, with investors reacting to the acquisition's cost and the flat Q4 revenue. The company's shares traded at $120.50, down from $130.00 before the announcement.
Outlook:
Cardinal Health raised its 2026 non-GAAP EPS guidance to $9.30 to $9.50, a 13% to 15% increase from the previous guidance. The company expects revenue growth of 11% to 13% for the Pharmaceutical and Specialty Solutions segment, 2% to 4% for the Global Medical Products and Distribution segment, and 26% to 28% for the Other segment [1].
References:
[1] https://newsroom.cardinalhealth.com/2025-08-12-Cardinal-Health-Reports-Fourth-Quarter-and-Fiscal-Year-2025-Results-and-Raises-Fiscal-Year-2026-Guidance

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios